Comparative analysis of SIV Gag specific effector and memory CD8 T cells induced by different adenovirus vectors.

/in

Tan WG, Jin HT, West EE, Penaloza-Macmaster P, Wieland A, Zilliox MJ, McElrath MJ, Barouch DH, Ahmed R. Comparative analysis of SIV Gag specific effector and memory CD8 T cells induced by different adenovirus vectors. J. Virol. 2013; 87:1359-1372.

Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies.

/in

Del Prete GQ, Scarlotta M, Newman L, Reid C, Parodi LM, Roser JD, Oswald K, Marx PA, Miller CJ, Desrosiers RC, Barouch DH, Pal R, Piatak M Jr, Chertova E, Giavedoni LD, O’Connor DH, Lifson JD, Keele BF. Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J. Virol. 2013; 87:4584-4595.

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).

/in , ,

Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, Abbink P, Peter L, Iampietro MJ, Cheung A, Pau MG, Weijtens M, Goudsmit J, Swann E, Wolff M, Loblein H, Dolin R, Barouch DH. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J. Infect. Dis. 2013; 207:240-247.

GagPol-specific CD4+ T-cells increase the antibody response to Env by intrastructural help.

/in

Nabi G, Genannt Bonsmann MS, Tenbusch M, Gardt O, Barouch DH, Temchura V, Uberla K. GagPol-specific CD4+ T-cells increase the antibody response to Env by intrastructural help. Retrovirology 2013; 10:117.

Generation of effector memory T-cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination.

/in

Li AV, Moon JJ, Abraham W, Suh H, Elkhader J, Seidman MA, Yen M, Im EJ, Foley MH, Barouch DH, Irvine DJ. Generation of effector memory T-cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci. Trans. Med. 2013; 5:204ra130.

Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.

/in ,

Stephenson KE, Hural J, Buchbinder SP, Sinangil F, Barouch DH. Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials. J. Infect. Dis. 2012; 205:1806-1810.

The number of TLR9-agonist motifs in the adenovirus genome correlates with induction of DC maturation by adenovirus immune complexes.

/in

Perreau M, Welles HC, Pellaton C, Gjoksi B, Potin L, Martin R, Harari A, Bett A, Casimiro D, Gall J, Barouch DH, Kremer EJ, Pantaleo G. The number of TLR9-agonist motifs in the adenovirus genome correlates with induction of DC maturation by adenovirus immune complexes. J. Virol. 2012; 86:6279-6285.

Vaccination with adenovirus serotypes 35, 26, and 48 elicits greater innate cytokine responses than adenovirus serotype 5 in rhesus monkeys.

/in

Teigler JE, Iampietro MJ, Barouch DH. Vaccination with adenovirus serotypes 35, 26, and 48 elicits greater innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J. Virol. 2012; 86:9590-9598.

Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys.

/in

Liu J, Li H, Iampietro MJ, Barouch DH. Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys. J. Virol. 2012; 86:7829-7835.

Ad5-specific neutralizing antibodies target multiple hexon hypervariable regions.

/in

Bradley RR, Maxfield LF, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH. Ad5-specific neutralizing antibodies target multiple hexon hypervariable regions. J. Virol. 2012; 86:1267-1272.